ENvue Medical (FEED) risk factors
Item 1A of every ENvue Medical, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors68 risks9 new29 dropped19 reworded
Merger integration and post-merger operations create significant stock volatility and business uncertainties for NanoVibronix and ENvue Holdings. Financing restrictions, preferred stock conversions, and cumulative dividend requirements risk severe shareholder dilution. Ongoing arbitration awards totaling $2.3 million to Protrade threaten company liquidity and financial condition.
Filed Apr 15, 2026 - FY2024 10-K risk factors88 risks
This company has no prior year risk factors on file. The risk section is dominated by merger-related risks, going concern doubts, regulatory dependencies for medical devices, and operational exposure in Israel.
Filed Mar 31, 2025